IART Key Statistics, Chart & Performance
The current stock price of IART is 11.04 USD. In the past month the price decreased by -14.17%. In the past year, price decreased by -57.26%.
IART Technical Analysis
IART Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IART. While IART is still in line with the averages on profitability rating, there are concerns on its financial health.
IART Financial Highlights
Over the last trailing twelve months IART reported a non-GAAP Earnings per Share(EPS) of 2.37. The EPS decreased by -4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| Debt/Equity | 1.73 |
IART Forecast & Estimates
17 analysts have analysed IART and the average price target is 15.81 USD. This implies a price increase of 43.21% is expected in the next year compared to the current price of 11.04.
For the next year, analysts expect an EPS growth of -12.33% and a revenue growth 1.09% for IART
IART Ownership
IART Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.06 | 189.572B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.89 | 169.763B | ||
| SYK | STRYKER CORP | 23.97 | 137.985B | ||
| BSX | BOSTON SCIENTIFIC CORP | 22.62 | 135.821B | ||
| BDX | BECTON DICKINSON AND CO | 13.79 | 58.939B | ||
| IDXX | IDEXX LABORATORIES INC | 43.07 | 50.51B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.52 | 47.643B | ||
| RMD | RESMED INC | 20.73 | 36.698B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.31 | 35.886B | ||
| DXCM | DEXCOM INC | 28.49 | 27.937B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IART
Company Profile
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,396 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Company Info
INTEGRA LIFESCIENCES HOLDING
1100 Campus Road
Princeton NEW JERSEY 08540 US
CEO: Peter J. Arduini
Employees: 4396
Phone: 16092750500
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you describe the business of INTEGRA LIFESCIENCES HOLDING?
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,396 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
What is the current price of IART stock?
The current stock price of IART is 11.04 USD. The price increased by 2.41% in the last trading session.
Does IART stock pay dividends?
IART does not pay a dividend.
How is the ChartMill rating for INTEGRA LIFESCIENCES HOLDING?
IART has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is IART stock listed?
IART stock is listed on the Nasdaq exchange.
What sector and industry does INTEGRA LIFESCIENCES HOLDING belong to?
INTEGRA LIFESCIENCES HOLDING (IART) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How many employees does INTEGRA LIFESCIENCES HOLDING have?
INTEGRA LIFESCIENCES HOLDING (IART) currently has 4396 employees.